Assistant Professor of Medicine

Research Description
Dr. Cahill’s utilizes translational approaches to identify how cells and mediators of the innate immune system contribute to novel mechanisms driving subphenotypes of adult asthma. Aspirin-exacerbated respiratory disease (AERD) is a subphenotype of adult asthma with a prominent role for interleukin (IL)-33, mast cells, and platelet-mediated inflammation. I have identified prostaglandin D2 generation during aspirin-induced reactions drives symptom severity and the role of TSLP and mast cells in this process, determined the effects of high-dose aspirin therapy in AERD on mast cells, and identified a subset which responds to inhibition of platelets with prasugrel. Additional work using imatinib, a tyrosine kinase inhibitor of KIT and thereby mast cells, in a randomized-controlled trial in a cohort of steroid-refractory severe asthmatics identified a role for KIT inhibition in improving methacholine airway hyperresponsiveness. I have successfully recruited more than 150 asthmatics into high-risk translational, stage II, and stage III investigator-initiated clinical trials involving airway provocation testing and developed the infrastructure for an asthma patient registry of over 1000 subjects. My clinical expertise in the diagnosis and management of adult asthma compliments my experience executing mechanistic studies involving assessments of respiratory and systemic inflammation and mediator production. Since my transition to Vanderbilt University in August 2018, my work has focused on translating preclinical data supporting Glucagon-Like Peptide (GLP)-1 receptor agonists are effective in animal models of obese asthma. Through collaborations with experts in obesity and metabolism, animal models of airway inflammation, and platelet biology at Vanderbilt, my goal is to define the mechanisms by which the GLP-1 receptor pathway attenuates inflammation in the obese and AERD phenotypes of adult asthma.
Research Keywords

Aspirin-exacerbated Respiratory Disease (AERD), Adult-onset Asthma, NSAID drug allergy, Chronic Rhinosinusitis with Nasal Polyps, Clinical Trials, Eicosanoid Biology, Cells and Mediators of Allergic Inflammation

Postgraduate Training

Internal Medicine – Beth Israel Deaconess Medical Center, Harvard Medical School, 2008
Internal Medicine - Beth Israel Deaconess Medical Center, Harvard Medical School, 2010
Allergy/Immunology – Brigham and Women’s Hospital, Harvard Medical School, 2013
Dr. Cahill sees patients at the Vanderbilt Asthma, Sinus and Allergy Program. Her clinical interests include the evaluation and management of adult-onset asthma, aspirin-exacerbated respiratory disease (AERD), NSAID drug allergy, and eosinophilic diseases.
Previous Institution
Brigham and Women's Hospital

Office Address:
1161 21st Ave S, MCN, Room / Suite T-1218, Nashville, TN 37232
Ringoes, NJ
Previous Role/Title
Assistant Professor of Medicine
Allergy & Immunology


MD - Robert Wood Johnson Medical School
BA - Pepperdine University

Laidlaw TM, Cahill KN, Cardet JC, Murphy K, Cui J, Dioneda B, Kothari P, Raby BA, Israel E, Boyce JA. A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory diseaseJ. Allergy Clin. Immunol [print-electronic]. 2018 Jun 6/8/2018; PMID: 29890239, PII: S0091-6749(18)30843-1, DOI: 10.1016/j.jaci.2018.06.001, ISSN: 1097-6825. 

Tuttle KL, Buchheit KM, Laidlaw TM, Cahill KNA retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory diseaseJ Allergy Clin Immunol Pract [print-electronic]. 2018 May; 6(3): 1045-7. PMID: 29501519, PMCID: PMC5997393, PII: S2213-2198(18)30118-1, DOI: 10.1016/j.jaip.2018.01.038, ISSN: 2213-2201. 

Schneider TR, Johns CB, Palumbo ML, Murphy KC, Cahill KN, Laidlaw TM. Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot TrialJ Allergy Clin Immunol Pract [print-electronic]. 2018 May; 6(3): 825-31. PMID: 29133219, PMCID: PMC5945343, PII: S2213-2198(17)30794-8, DOI: 10.1016/j.jaip.2017.10.011, ISSN: 2213-2201. 

Cahill KN, Boyce JA, Israel E. Novel Treatments for Airway Disease [letter]N. Engl. J. Med. 2017 Aug 8/10/2017; 377(6): 597. PMID: 28813135, PII: 10.1056/NEJMc1708004#SA5, DOI: 10.1056/NEJMc1708004, ISSN: 1533-4406. 

Cahill KN, Katz HR, Cui J, Lai J, Kazani S, Crosby-Thompson A, Garofalo D, Castro M, Jarjour N, DiMango E, Erzurum S, Trevor JL, Shenoy K, Chinchilli VM, Wechsler ME, Laidlaw TM, Boyce JA, Israel E. KIT Inhibition by Imatinib in Patients with Severe Refractory AsthmaN. Engl. J. Med. 2017 May 5/18/2017; 376(20): 1911-20. PMID: 28514613, PMCID: PMC5568669, DOI: 10.1056/NEJMoa1613125, ISSN: 1533-4406. 

Laidlaw TM, Cahill KNCurrent Knowledge and Management of Hypersensitivity to Aspirin and NSAIDsJ Allergy Clin Immunol Pract. 2017 May; 5(3): 537-45. PMID: 28483309, PII: S2213-2198(16)30559-1, DOI: 10.1016/j.jaip.2016.10.021, ISSN: 2213-2201. 

Cahill KN, Boyce JA. Aspirin-exacerbated respiratory disease: Mediators and mechanisms of a clinical disease [editorial]J. Allergy Clin. Immunol [print-electronic]. 2017 Mar; 139(3): 764-6. PMID: 27771324, PII: S0091-6749(16)31187-3, DOI: 10.1016/j.jaci.2016.09.025, ISSN: 1097-6825. 

Cahill KN, Johns CB, Cui J, Wickner P, Bates DW, Laidlaw TM, Beeler PE. Automated identification of an aspirin-exacerbated respiratory disease cohortJ. Allergy Clin. Immunol [print-electronic]. 2017 Mar; 139(3): 819-825.e6. PMID: 27567328, PMCID: PMC5266739, PII: S0091-6749(16)30700-X, DOI: 10.1016/j.jaci.2016.05.048, ISSN: 1097-6825. 

Cahill KN, Laidlaw TM. Pathogenesis of Aspirin-Induced Reactions in Aspirin-Exacerbated Respiratory DiseaseImmunol Allergy Clin North Am [print-electronic]. 2016 Nov; 36(4): 681-91. PMID: 27712763, PII: S0889-8561(16)30050-9, DOI: 10.1016/j.iac.2016.06.005, ISSN: 1557-8607. 

Shah NH, Schneider TR, DeFaria Yeh D, Cahill KN, Laidlaw TM. Eosinophilia-Associated Coronary Artery Vasospasm in Patients with Aspirin-Exacerbated Respiratory DiseaseJ Allergy Clin Immunol Pract [print-electronic]. 2016 Nov; 4(6): 1215-9. PMID: 27396680, PMCID: PMC5107156, PII: S2213-2198(16)30159-3, DOI: 10.1016/j.jaip.2016.04.028, ISSN: 2213-2201. 

Buchheit KM, Cahill KN, Katz HR, Murphy KC, Feng C, Lee-Sarwar K, Lai J, Bhattacharyya N, Israel E, Boyce JA, Laidlaw TM. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory diseaseJ. Allergy Clin. Immunol [print-electronic]. 2016 May; 137(5): 1566-1576.e5. PMID: 26691435, PMCID: PMC4860132, PII: S0091-6749(15)01576-6, DOI: 10.1016/j.jaci.2015.10.020, ISSN: 1097-6825. 

Cahill KN, Raby BA, Zhou X, Guo F, Thibault D, Baccarelli A, Byun HM, Bhattacharyya N, Steinke JW, Boyce JA, Laidlaw TM. Impaired E Prostanoid2 Expression and Resistance to Prostaglandin E2 in Nasal Polyp Fibroblasts from Subjects with Aspirin-Exacerbated Respiratory DiseaseAm. J. Respir. Cell Mol. Biol. 2016 Jan; 54(1): 34-40. PMID: 26051534, PMCID: PMC4742927, DOI: 10.1165/rcmb.2014-0486OC, ISSN: 1535-4989. 

Stevens W, Buchheit K, Cahill KNAspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and AnaphylaxisCurr Allergy Asthma Rep. 2015 Dec; 15(12): 69. PMID: 26475526, PII: 10.1007/s11882-015-0569-2, DOI: 10.1007/s11882-015-0569-2, ISSN: 1534-6315.

Lee-Sarwar K, Johns C, Laidlaw TM, Cahill KNTolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease [letter]J Allergy Clin Immunol Pract [print-electronic]. 2015 May; 3(3): 449-51. PMID: 25634222, PMCID: PMC4426242, PII: S2213-2198(15)00012-4, DOI: 10.1016/j.jaip.2015.01.007, ISSN: 2213-2201. 

Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D2: a dominant mediator of aspirin-exacerbated respiratory diseaseJ. Allergy Clin. Immunol [print-electronic]. 2015 Jan; 135(1): 245-52. PMID: 25218285, PMCID: PMC4289104, PII: S0091-6749(14)01030-6, DOI: 10.1016/j.jaci.2014.07.031, ISSN: 1097-6825. 

Cahill KN, Laidlaw TM. Aspirin exacerbated respiratory disease: the search for a biomarker [editorial]Ann. Allergy Asthma Immunol [print-electronic]. 2014 Nov; 113(5): 500-1. PMID: 25442693, PII: S1081-1206(14)00598-5, DOI: 10.1016/j.anai.2014.08.017, ISSN: 1534-4436. 

Hong DI, Bankova L, Cahill KN, Kyin T, Castells MC. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapiesExpert Rev Clin Immunol. 2012 Jan; 8(1): 43-52; quiz 53. PMID: 22149339, DOI: 10.1586/eci.11.75, ISSN: 1744-8409. 

Cahill KN, Kucharik CJ, Foley JA. Prairie restoration and carbon sequestration: difficulties quantifying C sources and sinks using a biometric approachEcol Appl. 2009 Dec; 19(8): 2185-201. PMID: 20014587, ISSN: 1051-0761. 

Hayhoe K, Cayan D, Field CB, Frumhoff PC, Maurer EP, Miller NL, Moser SC, Schneider SH, Cahill KN, Cleland EE, Dale L, Drapek R, Hanemann RM, Kalkstein LS, Lenihan J, Lunch CK, Neilson RP, Sheridan SC, Verville JH. Emissions pathways, climate change, and impacts on CaliforniaProc. Natl. Acad. Sci. U.S.A [print-electronic]. 2004 Aug 8/24/2004; 101(34): 12422-7. PMID: 15314227, PMCID: PMC514653, PII: 0404500101, DOI: 10.1073/pnas.0404500101, ISSN: 0027-8424.